| pubmed-article:11180090 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11180090 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:11180090 | lifeskim:mentions | umls-concept:C0017636 | lld:lifeskim |
| pubmed-article:11180090 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:11180090 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:11180090 | lifeskim:mentions | umls-concept:C1518321 | lld:lifeskim |
| pubmed-article:11180090 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11180090 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11180090 | pubmed:abstractText | The median survival for patients with glioblastoma is reported to be 12 months. To improve the outcome for glioblastoma patients, the authors evaluated the therapeutic efficacy of preirradiation gemcitabine chemotherapy followed by standard radiotherapy. | lld:pubmed |
| pubmed-article:11180090 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11180090 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11180090 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11180090 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11180090 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11180090 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11180090 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11180090 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11180090 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:11180090 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:WellerMM | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:MeyermannRR | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:DichgansJJ | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:BambergMM | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:HeissEE | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:WickWW | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:KortmannR DRD | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:KükerWW | lld:pubmed |
| pubmed-article:11180090 | pubmed:author | pubmed-author:StrefferJJ | lld:pubmed |
| pubmed-article:11180090 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11180090 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11180090 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:11180090 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11180090 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11180090 | pubmed:pagination | 423-7 | lld:pubmed |
| pubmed-article:11180090 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:meshHeading | pubmed-meshheading:11180090... | lld:pubmed |
| pubmed-article:11180090 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11180090 | pubmed:articleTitle | Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. | lld:pubmed |
| pubmed-article:11180090 | pubmed:affiliation | Department of Neurology, University of Tübingen Medical School, Tübingen, Germany. michael.weller@tuebingen.de | lld:pubmed |
| pubmed-article:11180090 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11180090 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11180090 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11180090 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11180090 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11180090 | lld:pubmed |
